{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:55:20Z","timestamp":1762001720477},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/inf.0b013e3182886377","type":"journal-article","created":{"date-parts":[[2013,2,22]],"date-time":"2013-02-22T10:00:49Z","timestamp":1361527249000},"page":"636-640","source":"Crossref","is-referenced-by-count":37,"title":["Etiology, Extended-spectrum \u03b2-lactamase Rates and Antimicrobial Susceptibility of Gram-negative Bacilli Causing Intra-abdominal Infections in Patients in General Pediatric and Pediatric Intensive Care Units\u2014Global Data From The Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010"],"prefix":"10.1097","volume":"32","author":[{"given":"Robert E.","family":"Badal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel K.","family":"Bouchillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle H.","family":"Lob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Hawser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01169-07","article-title":"ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli.","volume":"52","author":"Giske","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/CCM.0b013e31819ced02","article-title":"Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit.","volume":"37","author":"Shorr","year":"2009","journal-title":"Crit Care Med"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2009.06.009","article-title":"Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.","volume":"66","author":"Hoban","year":"2010","journal-title":"Diag Microbiol Infect Dis"},{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/sur.2009.057","article-title":"Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study.","volume":"11","author":"Hawser","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"issue":"suppl 1","key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","article-title":"Prevalence and spread of extended-spectrum -lactamase-producing Enterobacteriaceae in Europe.","volume":"14","author":"Canton","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jac\/dki166","article-title":"Emergence of Enterobacteriaceae producing extended-spectrum -lactamases (ESBLs) in the community.","volume":"56","author":"Pitout","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"19044","DOI":"10.2807\/ese.13.47.19044-en","article-title":"Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe.","volume":"13","author":"Coque","year":"2008","journal-title":"Euro Surveill"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe.","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1128\/JCM.02353-09","article-title":"Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.","volume":"48","author":"Rodriguez-Bano","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2012.05.024","article-title":"Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010.","volume":"74","author":"Hoban","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/AAC.00322-06","article-title":"In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.","volume":"50","author":"Souli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1179\/joc.2009.21.3.261","article-title":"Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains.","volume":"21","author":"Jamal","year":"2009","journal-title":"J Chemother"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhin.2009.02.021","article-title":"Extended-spectrum beta-lactamase-producing organisms.","volume":"73","author":"Falagas","year":"2009","journal-title":"J Hosp Infect"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e3182886377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:43:31Z","timestamp":1644392611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201306000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3182886377","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}